LSU AgCenter Therapeutic Cannabis Program

LSU AgCenter selects vendor for therapeutic cannabis program

As of September 14, 2017, the LSU AgCenter finalized their agreement with GB Sciences Louisiana, LLC, a wholly-owned subsidiary of GB Sciences, Inc., to produce therapeutic cannabis products for qualifying patients.

GB Sciences is a cannabis company focused on biopharmaceutical development, and has filed patent applications for use of cannabis with chronic pain and heart therapies, as well as chronic arthritis, Crohn’s disease, inflammatory bowel disease and asthma.

GB Sciences will produce therapeutic cannabis under the LSU AgCenter’s license for patients with very specific conditions.

In compliance with the Alison Neustrom Act, approved medical care providers will oversee patients with debilitating conditions including cancer, HIV, epilepsy and spasticity. Patients who have exhausted other medical options without a positive result may be recommended therapeutic cannabis by their practitioner, through specific delivery methods and specified dosages.

The LSU AgCenter has been working closely with state regulators including the Louisiana Department of Agriculture and Forestry, the Louisiana Board of Pharmacy and the Louisiana State Board of Medical Examiners to ensure that patient and public safety are at the forefront.

The Louisiana State Board of Medical Examiners has developed stringent guidelines for doctors to recommend therapeutic cannabis, including regular follow-ups and reporting.

Delivery methods are limited to oils, oral methods such as pills, sprays or chewables, topical applications, transdermal patches and suppositories. Louisiana law does not allow for any product to be inhaled, raw or smoked.

GB Sciences will begin renovation of their production facility immediately and anticipate product availability for patients by the middle of next year. The production facility will not be located on LSU’s campus, and no students as well as anyone under 21 years old will be employed in the facility.

Under the terms of the agreement, the LSU AgCenter will receive $3.4 million or 10 percent of gross revenue, whichever is greater, over five years. GB Sciences will support LSU AgCenter research through funding for personnel, laboratory research space and equipment and an additional monetary contribution for research initiatives.

As the licensee, the LSU AgCenter is authorized to conduct research on therapeutic cannabis. The LSU AgCenter has had preliminary discussions with Pennington Biomedical Research Center and the Health Science Centers in New Orleans and Shreveport on opportunities for research collaboration.

Research will likely include variety development, growth management practices, extraction techniques, compound identification and isolation, drug delivery methods and efficacy testing.

GB Sciences will be responsible for the cultivation, extraction, processing, and production of therapeutic cannabis and will provide and perform all other necessary activities to provide usable theriapeutic cannabis products for patients through licensed dispensary pharmacies.

As a public institution of higher education, the LSU AgCenter’s partnership with GB Sciences represents a first in the therapeutic cannabis industry.

Representatives from the LSU AgCenter visited the GB Sciences production facility in Las Vegas, Nevada.

The LSU AgCenter chose GB Sciences following a rigorous selection process for this collaboration.

No taxpayer dollars will be spent on the project.

Patient Information

The LSU AgCenter and GB Sciences anticipate production facility construction and renovations to be completed in the first quarter of 2018, and anticipate product availability by mid-year. All products must be sold in a dispensary approved by the Louisiana Board of Pharmacy.

Qualifying Conditions

  • Cancer
  • Positive status for Human Immunodeficiency Virus (HIV)
  • Acquired Immune Deficiency Syndrome (AIDS)
  • Cachexia or wasting syndrome
  • Seizure disorders
  • Epilepsy
  • Spasticity
  • Crohn’s disease
  • Muscular dystrophy
  • Multiple sclerosis

Allowable Delivery Methods

  • No raw or inhaled products
  • Oils, extracts, tinctures or sprays
  • Solid oral dosage forms, e.g., capsules or pills
  • Liquid oral dosage forms, e.g., solutions or suspensions
  • Edible dosage forms (chewable)
  • Topical applications, oils or lotions
  • Transdermal patches
  • Suppositories

Patient Recommendations

Patients with qualifying medical conditions should discuss medical opportunities with their physicians.

The Louisiana State Board of Medical Examiners has developed rules relative to the recommendation of therapeutic cannabis by licensed physicians. Regulations include mandatory testing and qualifying by physicians and regular reporting of patient status. Additional information on the Board of Medical Examiners can be found at www.lsbme.la.gov .

Physician Registration

The Louisiana State Board of Medical Examiners requires physicians complete an online registration course. CLICK HERE for the online Board Orientation and Courses.

For information on the Physician requirements and instructions for application, view attached .pdf.: LSBME PACKETpdf

Licensed Dispensaries

Louisiana law limits the number of pharmacies to dispense therapeutic cannabis to ten licenses. These pharmacies will be selected by the Louisiana Board of Pharmacy through an application process. Additional information can be found at www.pharmacy.la.gov .

Regulations and Enforcement

The Louisiana Department of Agriculture and Forestry are named as the regulatory agency for the licensees. Information on the regulations can be found at www.ldaf.state.la.us, or click here for the current rules.


LSBME Instruction Packet

News Releases

LSU AgCenter selected a vendor for medical marijuana

(06/15/17) BATON ROUGE, La. — The LSU AgCenter has notified the Board of Supervisors of their intent to contract with GB Sciences, Inc., to produce a medical marijuana product for qualifying patients. GB Sciences will work under the LSU AgCenter license in compliance with state law and rules established by regulatory agencies.
http://www.lsuagcenter.com/profiles/rbogren/articles/page1497539347067


Agriculture and Medicine

While Louisiana has had legislation since the late 1970s regarding medical marijuana, the lack of enabling rules and regulations prevented patient access until the passage of Senate Bill 143 in 2015. Sen. Fred Mills, of Breaux Bridge, authored the legislation, paving the way for the production, recommendation and use of medical marijuana. The act (La R.S. 40:1046) became known as the Alison Neustrom Act, in honor of Dr. Alison Neustrom, of Lafayette, who was an advocate for medical marijuana. At 42, Dr. Neustrom passed away from aggressive pancreatic cancer.
http://www.lsuagcenter.com/profiles/lbenedict/articles/page1491493091171


LSU AgCenter opts in to medical marijuana production initiative

(06/24/16) BATON ROUGE, La. – The LSU Board of Supervisors on Friday (June 24) approved a resolution allowing the LSU AgCenter to begin taking steps needed to obtain a license to produce medical marijuana as part of a state initiative.
http://www.lsuagcenter.com/profiles/rbogren/articles/page1466797308857

The Louisiana Law for Therapeutic Use of Marijuana

PART X-E. THERAPEUTIC USE OF MARIJUANA

§1046. Prescription of marijuana for therapeutic use; rules and regulations; Louisiana Board of Pharmacy and the adoption of rules and regulations relating to the dispensing of prescribed marijuana for therapeutic use; the Department of Agriculture and Forestry and the licensure of a production facility.

For the full law go to this link: http://www.legis.la.gov/Legis/Law.aspx?d=96986

Will there be a research and development component added to the initiative?

The potential for research in both the plant strain development arena and in extraction, formulation and compounding of the drug are important elements in the initiative. The law, as signed by the governor, addressed research separate and apart from production. Future success of the initiative will depend in part on our ability to produce superior plants using our biotechnology techniques to develop strains for expression of specific compounds in the plant. Equally important will be the opportunity for basic clinical research conducted by the Pennington Biomedical Research Center and the LSU Health Sciences Center to formulate and compound the drug compounds to certain disease states as outlined in the law. Research and data collection also ensure that science is directing the future of the program.

Innovate . Educate . Improve Lives

The LSU AgCenter and the LSU College of Agriculture

Top